KFDA to reshuffle drug review standards substantially.

Published: 2004-03-12 07:00:00

Updated: 2004-03-12 07:00:00

KFDA intends to set up more detailed plans for the quality assurance of drugs on the market and its safety controls by adopting a new system for those drugs to be reviewed in its safety and efficacy at any time without giving any advanced notification so far in practice, for the inducement of an ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK